VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by University Medical Centre Groningen.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
UMC Utrecht
Information provided by (Responsible Party):
G.M. van Dam, University Medical Centre Groningen
ClinicalTrials.gov Identifier:
NCT01508572
First received: December 22, 2011
Last updated: March 19, 2012
Last verified: March 2012
  Purpose

The purpose of this study is to determine the uptake, (semi-)quantification and localization of the VEGF targeting fluorescent tracer bevacizumab-IDRye800CW in breast cancer tissue, surrounding healthy tissue, tumor margins and lymph nodes. This is measured in surgical specimens after a single intravenous administration of 4,5 bevacizumab-IDRye800CW, using fluorescence microscopy and macroscopy techniques. Also the safety of bevacizumab-IDRye800CW is assessed. Another purpose is to assess the abilities of three different fluorescent signal detection systems to detect the fluorescent signal pre- and intra-operatively.


Condition Intervention Phase
Breast Cancer
Drug: bevacizumab-IRDye800CW
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Validation of Uptake of a VEGF-targeted Optical Fluorescent Imaging Tracer in Surgical Specimens of Breast Cancer and Application of Pre- and Intra-operative Human Molecular Fluorescence Imaging Techniques. A Multicenter Feasibility Study

Resource links provided by NLM:


Further study details as provided by University Medical Centre Groningen:

Primary Outcome Measures:
  • The uptake of bevacizumab-IRDye800CW in breast cancer tissue, surrounding tissue and lymph nodes in surgical specimens by fluorescence microscopy and macroscopy [ Time Frame: After the last patient is included, which is expected to be within one year after the first inclusion ] [ Designated as safety issue: No ]

    Outcome measures:

    • The accumulation, tissue distribution, lokalization and (semi) quantification of bevacizumab-IRDye800CW in breast cancer tissue, surrounding tissue and lymph nodes. Measured by macroscopy using MSOT, Odessey and MFRI and by microscopy using fluorescence microscope and Odessey.
    • Correlation of the above to VEGF-levels and other biological parameters.

  • Occurrence of adverse events as a measure of safety and tolerability of bevacizumab-IRDye800CW [ Time Frame: Participants will be observed for the duration of hospital stay, an expected average of 4 hours after tracer injection. In case of adverse events, patients are observed and treated until recovery ] [ Designated as safety issue: Yes ]
    Obtaining information on safety aspects of bevacizumab-IRDye 800CW, side effects, AE, SAE, SUSAR by observing patients after tracer injection and follow up until 14 days after surgery


Secondary Outcome Measures:
  • Detection ability of preoperative optical fluorescence imaging techniques (FDOT; Fluorescence diffuse optical tomography and MSOT; multispectral opto-acoustic imaging) of the fluorescent signal from bevacizumab-IRDye800CW [ Time Frame: detection of the tracer is performed at 4h, 36h and 72h after tracer injection. ] [ Designated as safety issue: No ]
    • To assess and compare the presence of a fluorescent signal in breast cancer tissue and normal tissue
    • To explore pharmacokinetics and optical imaging time-points by peforming FDOT/MSOT at multiple time points after administration.
    • To correlate the fluorescence signal assessed by FDOT/MSOT with VEGF-levels, other biological parameters and the fluorescent signal assessed in the ex-vivo surgical specimen.

  • Detection ability of the intra-operative mulitspectral fluorescence reflectance imaging (MFRI) of the fluorescent signal from bevacizumab-IRDye 800CW during surgery [ Time Frame: 72 hours after tracter injection, during surgery. ] [ Designated as safety issue: No ]
    • To assess and compare the presence of a fluorescent signal in breast cancer tissue and normal tissue by assessing the images made by the MFRI during and after surgery.
    • the fluorescent signal assessed by MFRI will be correlated with VEGF levels in the ex-vivo surgical specimens.

  • Detection ability of all optical imaging techniques (FDOT, MSOT, MFRI) of the fluorescent signal in surgical specimens ex vivo [ Time Frame: after the last patient is operated, which is approximately one year after study start. ] [ Designated as safety issue: No ]
    Assessment of the ability of all optical imaging techniques (FDOT, MSOT, MFRI) to detect fluorescent signal in surgical specimens ex vivo by (semi) quantification of the images and to compare images between different techniques and different tissues (surrounding tissue, tumor tissue and lymph nodes)


Estimated Enrollment: 30
Study Start Date: October 2011
Estimated Study Completion Date: January 2013
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: bevacizumab-IRDye800CW
In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
Drug: bevacizumab-IRDye800CW
In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
Other Names:
  • Fluorescence tracer imaging
  • Beva-800CW
  • Bevacizumab-800CW

Detailed Description:

There is a need for better visualization of presence and extent of breast cancer to improve breast cancer management. Molecular imaging of breast cancer associated targets is a promising method to improve visualization. Vascular endothelial growth factor (VEGF) has proven to be a valid target for molecular imaging with radioactive labeled tracers. However in view of radiation safety, infrastructure, costs and stability, fluorescent labeling of bevacizumab (a VEGF targeting humanized monoclonal antibody) has potential advantages over radioactive labeling. Therefore recently the near-infrared fluorescent tracer bevacizumab-IRDye 800CW has been developed. In mice the fluorescent signal was clearly present in tumor tissue and could be visualized intra-operatively. The tracer was also approved for administration to patients in a microdose (tracer dose).

In this prospective multicenter feasibility study the new tracer bevacizumab-IRDye 800CW will be administered to a maximum of 30 patients with proven breast cancer 3 days before surgery. Part of the surgical specimen will after surgery extensively be investigated by macroscopy and microscopy to determine the uptake of the tracer in tumor tissue, surrounding normal tissue and lymph nodes. To detect the tracer before surgery, two different pre-operative imaging methods are used: MSOT (in the UMCG en FDOT in the UMCU. During surgery the intra-operative MFRI camera is available at both centers to detect the fluorescent signal.

The study consists of a total of five study procedure related patient visits.

  1. During a screening visit, eligibility will be evaluated and patient characteristics will be collected.
  2. During the administration visit, 3 days before surgery, 4.5 mg of bevacizumab-IRDye 800CW will be administered intravenously, followed by 4 hours observation. Also before and 4 hours after tracer injection pre-operative optical imaging will take place (in the UMC Groningen, the hand-held MSOT system will be used and in the UMC Utrecht, the FDOT system will be used) and blood samples are taken.
  3. A third visit, approximately 36 hours after tracer administration, another pre-operative optical imaging procedure will take place.
  4. At the day of surgery, first a blood sample will be taken and the last pre-operative optical imaging procedure will take place, followed by standard surgery. During surgery, the MFRI camera will be used to detect a fluorescent signal before and after incision an after removal of the tumor. Part of the surgical specimen will after surgery extensively be investigated by macroscopy and microscopy to determine the uptake of the tracer in tumor tissue, surrounding normal tissue and lymph nodes.
  5. At an outpatient visit (approximately 10 days after surgery) (visit 5), the last blood sample will be taken.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years.
  • Patients with proven breast cancer (cytology, histology) who are scheduled to receive operation intervention.
  • Tumor size of at least 15 mm diameter according to anatomical imaging data.
  • Signed written informed consent.
  • Able to comply with the protocol.
  • WHO performance score 0-2.

Exclusion Criteria:

  • Other invasive malignancy.
  • Serious other medical conditions.
  • Pregnant or lactating women. (Documentation of a negative pregnancy test must be available for pre-menopausal women with intact reproductive organs and for women less than two years after menopause).
  • Prior radiotherapy on the involved area.
  • Major surgery within 28 days before the initiation of the study.
  • Prior allergic reaction to immunoglobulins or immunoglobulin allergy.
  • Prior neo-adjuvant chemotherapy.
  • Breast prosthesis in target breast.

UMC Utrecht (FDOT) specific exclusion criteria

  • Breast is too big to fit in the biggest cup or is too small to fit in the smallest cup of the FDOT system.
  • Non-intact skin at time of the FDOT procedures.
  • Breast located skin diseases.
  • Piercings or tattoos located on the breast/nipple.
  • Contra-indication for MR procedures or claustrophobia.
  • Inability to lay prone positioned for the duration of the FDOT procedure (10 minutes) and MR procedure (30 minutes).
  • Tumor located close to the chest wall as assessed by breast imaging data.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01508572

Contacts
Contact: Go M. van Dam, MD, PhD +31 50 361 0183 g.m.van.dam@umcg.nl
Contact: Elisabeth G. de Vries, MD, PhD +31 50 361 2821 e.g.e.de.vries@umcg.nl

Locations
Netherlands
University Medical Center Groningen Recruiting
Groningen, Netherlands, 9713 GZ
Contact: Go M. van Dam, MD, PhD    +31 50 361 0183    g.m.van.dam@umcg.nl   
Contact: Elisabeth G. de Vries, MD, PhD    +31 50 361 2821    e.g.e.de.vries@umcg.nl   
Principal Investigator: Go M. van Dam, MD, PhD         
Sponsors and Collaborators
University Medical Centre Groningen
UMC Utrecht
Investigators
Principal Investigator: Go M. van Dam, MD, PhD University Medical Centre Groningen
  More Information

No publications provided

Responsible Party: G.M. van Dam, Principal Investigator, University Medical Centre Groningen
ClinicalTrials.gov Identifier: NCT01508572     History of Changes
Other Study ID Numbers: UMCG/UMCU_01, 2011-003083-75
Study First Received: December 22, 2011
Last Updated: March 19, 2012
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by University Medical Centre Groningen:
breast cancer
VEGF
optical imaging

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 24, 2014